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Introduction
Hairy cell leukemia (HCL) is an indolent lymphopro-
liferative malignancy characterized by infiltration of
the bone marrow, liver, spleen, and occasionally lymph
nodes with neoplastic B cells with cytoplasmic hair-like
projections.1 Diagnosis of HCL is historically based on
the unique appearance of neoplastic lymphocytes (hairy
cells), which are typically tartrate-resistant acid phos-
phatase (TRAP) stain-positive, and morphologic fea-
tures of bone marrow and/or spleen. By the method
of immunophenotyping, hairy cells express the pan 
B-cell antigens CD19, CD20 and CD22, as well as
monoclonal surface immunoglobulin of IgG or mul-
tiple heavy chain isotypes. Characteristically, they also
express CD11c, CD25 and CD103.2
Splenectomy used to be the standard treatment
option, leading to significant improvements in cytope-
nia, but only of limited duration.3 Recently, nucleoside
analogs such as 2-chlorodeoxyadenosine (2-CDA or
cladribine) and 2-deoxycoformycin (DCF or pento-
statin) have been successfully used to treat patients with
HCL.4 In Western countries, the overall response rate
to cladribine ranged from 75% to 100% after a single
course.5,6 However, to our knowledge, there are only
2 case reports about treatment results with cladribine
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in Taiwan.7,8 In this study, we describe the clinico-
pathologic features of 5 HCL patients and the treatment
outcome with combined splenectomy and cladribine.
Methods
Patients
Between December 1996 and June 2005, 33 patients
who were diagnosed with malignant lymphoma and
who underwent splenectomy were sampled. Five
patients were identified with HCL based on clinical pic-
ture and pathologic features of bone marrow and spleen,
including electromicroscopic findings and immuno-
phenotyping results (pan B-antigens and DBA44 in 
2 patients). All patients were treated with splenectomy
followed by cladribine. Cladribine was administered at a
dosage of 0.1mg/kg/day by continuous intravenous
infusion for 7 days as described previously.6 Complete
blood counts (CBCs) were reviewed monthly and
tumor response was assessed according to the following
criteria: complete response (CR) was defined as the dis-
appearance of hairy cells from the peripheral blood and
bone marrow, disappearance of lymph node enlarge-
ment and hepatomegaly, and normalization of the neu-
trophil count (≥ 1.5 × 109/L), platelet count (≥ 100 ×
109/L) and hemoglobin level (≥ 12 g/dL). Partial
response (PR) was defined as ≥ 50% decrease in hairy
cells in the peripheral blood and bone marrow, ≥ 50%
decrease in lymphadenopathy and hepatomegaly, and
normalization of the neutrophil and platelet counts.
Statistical analysis
Because of the limited number of cases studied, only
descriptive statistics are presented.
Results
Clinical findings
The clinical features of the 5 cases are summarized 
in Table 1. There were 3 men and 2 women, and the
median age was 47 years (range, 27–77 years). All
patients presented with splenomegaly, and the weight
of the spleen ranged from 372 g to 5,000 g. None
had peripheral lymphadenopathy except 1 who had
retroperitoneal lymphadenopathy. Pancytopenia was
noted in all 3 men. Leukocytosis, especially lympho-
cytosis, was noted in the 2 women.
Pathologic findings
As presented in Table 2, the typical neoplastic leukemic
cells (hairy cells) in peripheral blood were identified in
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only cases 4 and 5 (the 2 women with lymphocytosis).
Bone marrow examinations were done in all patients,
but only 3 patients were diagnosed with HCL based
solely on the bone marrow findings (Figure 1). In con-
trast, HCL was diagnosed in all spleen pathologic speci-
mens. Immunophenotypic findings revealed that hairy
cells possessed pan B-cell antigens (CD20 and/or
CD22) in all cases, and DBA44 stain was positive in 
2 cases (not available for the other 3 cases). A moderate
degree of bone marrow fibrosis was noted in cases 1 and
3 but was not consistent with the degree of splenome-
galy. No cytogenetic abnormality was identified; how-
ever, there were no metaphase cells in 1 case.
Treatment
As shown in Table 3, all patients underwent splenec-
tomy either at the time of diagnosis or immediately after
diagnosis (median time from diagnosis to splenectomy
was 2 days; range, 0–49 days), with no major complica-
tions noted. Due to reasons related to national insur-
ance coverage and the complex process of license
approval of cladribine by the National Department of
Health, cladribine was administered after splenec-
tomy at a median time of 2 months from diagnosis
(range, 0.5–5 months). There were no significant acute
or chronic side effects except for 1 episode of grade 4
neutropenia. Figure 2 shows the changes in white
blood cell and platelet counts of these patients. Four
patients achieved CR at a median time of 2 months
(range, 2–6 months), and 1 patient achieved PR at 
4 months, but she returned to Vietnam and was thus
lost to follow-up. Tracing her CBC data with corre-
spondence, we found that it had normalized 1 year after
treatment. After a median follow-up of 29 months
(range, 4–96 months), all patients were alive without
severe infection or secondary malignancy.
Discussion
HCL appears to be a very uncommon disease in
Taiwan. Although there is no central registry for HCL
in Taiwan, the incidence of HCL in Hong Kong
Chinese was roughly estimated to be 0.35 cases per
1,000,000 persons per year.9 This is much lower than
the 0.2 per 100,000 persons per year reported in
Western series.10 Because of the rarity and unavailabil-
ity of cladribine in Taiwan until 1997, the treatment
outcome of HCL in Taiwan was seldom reported.
The present study, despite being only of 5 cases, is the
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Table 2. Pathologic features of the 5 patients with hairy cell leukemia
Patient Peripheral hairy cells TRAP stain* DBA44 stain† CD20† Bone marrow fibrosis Cytogenetics*‡
1 No Negative ND Positive Moderate 46,XY
2 No Negative ND Positive No 46,XY
3 No Negative ND Positive Moderate 46,XY
4 Yes Positive Positive Positive No 46,XX
5 Yes Positive Positive Positive No No metaphase cells
*Of peripheral blood hairy cells; †results of immunophenotyping from spleen specimens; ‡bone marrow specimens were used for cytogenetic analysis. TRAP =
tartrate-resistant acid phosphatase; ND = not done.
A B
Figure 1. (A) A lymphocyte with cytoplasmic hair-like projections (hairy cell) is present in peripheral blood (Wright stain, 400×). 
(B) Diffuse infiltration of small lymphocytes is noted in bone marrow; they have a “fried egg” appearance with the nucleus of each hairy
cell surrounded by a halo of cytoplasm (hematoxylin & eosin, 100×).
first and largest series concerning the treatment out-
come of this rare disease in Taiwan.
Generally, the clinicopathologic features of HCL in
Taiwanese patients are similar to that in Western coun-
tries. Of note, we found that the pathologic features of
the spleen were more characteristic and enabled the
diagnosis of HCL. In the spleen, hairy cell infiltrates
localize to the red pulp, and the white pulp is typically
atrophic. The cells infiltrate the red pulp cords exten-
sively and exhibit widely spaced nuclei and variable
nuclear indentations.2 Probably because of the clear
contrast and extensive involvement, diagnosis of HCL
from spleen is much easier than from bone marrow, in
which limited specimen and occasional hypocellularity
may confound the diagnosis. In our study, the diagnosis
of HCL could not be made by bone marrow findings
only in 2 patients. Limited specimen with hypocellularity
was the reason in 1 patient, and atypical features of hairy
cells in bone marrow accounted for the other. This
diagnostic viewpoint has never been paid much atten-
tion; however, it may have value in diagnosis since spe-
cific markers such as CD25 or CD103 are not routinely
available in pathology laboratories. Furthermore, the
morbidity and mortality of splenectomy was not high
due to advances in surgical technique.11 There were no
significant complications in any of our cases, and cyto-
penia, especially thrombocytopenia, recovered well in
most of them before cladribine therapy. Although in
the era of purine analogs, which are highly effective 
in HCL treatment, splenectomy is not routinely nec-
essary, splenectomy is not only 1 part of the treatment
but is conducive to the diagnosis in our study as
described above and could be considered in some
specific circumstances.
Two purine analogs are currently available to treat
HCL. Pentostatin is the first one reported to be highly
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Figure 2. Changes in (A) white blood cell count (WBC) and (B) platelet count in 5 patients with hairy cell leukemia over the whole course
of treatment. Pre-cladribine = before cladribine administration (post-splenectomy); Post-cladribine-1/2 = 14 days after cladribine admin-
istration; Post-cladribine-1 = 1 month after cladribine administration; Post-cladribine-3 = 3 months after cladribine administration; Post-
cladribine-6 = 6 months after cladribine administration.
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Table 3. Treatment outcome of the 5 patients with hairy cell leukemia
Patient TTS TTC Side effects
Pre-cladribine CBC
Remission TTCR Follow-up
(d) (mo) WBC (× 109/L) Hb (g/dL) PLT (× 109/L) (mo) (mo)
1 49 5 No 3.54 14.7 266 CR 2 96
2 0* 2 No 20.54 14.6 240 CR 6 49
3 44 3 WBC 560 on day 7 1.7 10.1 214 CR 2 29
4 0* 0.5 No 43.68 11.2 521 PR - 4†
5 2 0.5 No 27.17 10.2 177 CR 2 21
*Diagnosis by spleen pathology; †after 4 months, the patient returned to Vietnam, and CBC data was obtained by correspondence for follow-up. TTS = time
from diagnosis to splenectomy; TTC = time from splenectomy to cladribine; CBC = complete blood count; WBC = white blood cell count; Hb = hemoglobin; 
PLT = platelets; TTCR = time from cladribine to complete remission; CR = complete response; PR = partial response.
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effective in HCL, with the CR rate ranging from 82%
to 87%, and 5-year and 10-year overall survivals of about
90% and 80%, respectively.12 Cladribine also exerts a
dramatic response in HCL with a single treatment
course. Recently, a long-term follow-up report by
Chadha et al showed that overall response was 98%,
and 79% of patients who achieved CR had an overall
survival rate of 87% after 12 years.5 Because of their
effectiveness and safety, purine analogs have replaced
other treatment modalities to become first-line ther-
apy for HCL. Yang and Ho reported the first case of
HCL treated with splenectomy and cladribine in
2001.8 Long-term remission was achieved by splenec-
tomy and a single 7-day course of cladribine in a 48-
year-old man without significant adverse effects.
Chen et al presented another 2 cases, treated with
cladribine but not combined with splenectomy, who
experienced rapid (within 4–6 weeks) and durable
remission.7 In our study, excellent treatment outcome
by cladribine was also observed. Four of 5 (80%)
patients achieved CR within 2–6 months without signif-
icant adverse effects and had sustained response. Case 4
initially presented with marked leukocytosis and
appeared to have suboptimal response to cladribine.
After obtaining CBC data from correspondence, late
CR seemed to be achieved, although we could not
get her bone marrow or other data. In spite of typical
morphologic features and positive TRAP stain, HCL
variant should be suspected in this case. The rate of
secondary malignancy has been reported to be as high
as 17% in Western series,5 but none was noted in our
patients (who had a shorter follow-up duration).
In summary, the clinicopathologic features of
Taiwanese patients with HCL in our study did not
appear to differ from that of patients in Western series.
Splenectomy is safe and effective in ameliorating cytope-
nia and has great contribution to diagnosis. Similar to
the Western experience, cladribine produces an excel-
lent treatment outcome with acceptable side effects
and should be considered as first-line treatment for
HCL patients in Taiwan.
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